<DOC>
	<DOC>NCT01769170</DOC>
	<brief_summary>The purpose of this study is to compare the effectiveness of CMX001 to placebo for the prevention of CMV infection in stem cell transplant patient who do not have CMV before starting treatment with CMX001.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients</brief_title>
	<detailed_description />
	<criteria>Subjects will be adult allogeneic HSCT recipients aged â‰¥ 18 yearsold (or as applicable, per local law) who were CMV seropositive before transplantation and are CMV viremia negative posttransplant. Subjects who have a positive CMV viremia test at any time between transplant and the First Dose Day (FDD). Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients. Subjects who have received any antiCMV therapy and investigational antiCMV drugs at any time posttransplant. Subjects who have had any antiCMV vaccine at any time.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CMV</keyword>
	<keyword>Hematopoietic Stem Cell Transplant Recipients</keyword>
	<keyword>CMV seropositive</keyword>
</DOC>